Review



multitarget molecule  (MultiTarget Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MultiTarget Pharmaceuticals multitarget molecule
    Multitarget Molecule, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget+molecule/multitarget+molecule/pmc11243327-103-7-7
    Average 90 stars, based on 1 article reviews
    multitarget molecule - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Novel Alaninamide Derivatives with Drug-like Potential for Development as Antiseizure and Antinociceptive Therapies─In Vitro and In Vivo Characterization.
    Article Snippet: In fact, approximately 30% of patients with epilepsy have drug-resistant epilepsy (DRE) and do not respond to ASMs.2 DRE is a serious condition as it is associated with a risk of sudden unexpected death in epilepsy (SUDEP), as well as psychiatric, psychosocial, and medical complications, having a profound influence on the overall quality of life.3 One of the promising therapeutic strategies in DRE involves development of multimodal (multitarget/multifunctional) molecules modulating different molecular targets and thereby overcoming the issues associated with polytherapy, which is often used in this condition.

    Article Title: Exploring Multitarget Strategies for Membrane Protection in Alzheimer's Disease.
    Article Snippet: The exploration of multitarget molecules presents a promising avenue in the quest for effective therapeutic strategies against Alzheimer’s disease (AD), a multifactorial neurodegenerative disorder.. Traditional single-target drugs have shown limited success due to the complex interplay of pathological processes involved in AD.. Multitarget-directed ligands (MTDLs), designed to interact with multiple targets simultaneously, offer a more holistic approach to address the multifaceted nature of neurodegenerative diseases.

    Article Title: Myeloperoxidase as a therapeutic target for oxidative damage in Alzheimer's disease.
    Article Snippet: Multitarget molecules that, in addition to being MPO inhibitors, can inhibit Aβ aggregation have been identified.

    Article Title: Exploring Current Molecular Targets in the Treatment of Neovascular Age-Related Macular Degeneration toward the Perspective of Long-Term Agents.
    Article Snippet: Another approach consisted of using multitarget molecules such as faricimab that are able to bind different ligands like VEGF and Ang-2.

    Article Title: Neuroblastoma and its Target Therapies: A Medicinal Chemistry Review.
    Article Snippet: [106] the design of multitarget molecules[96] fits into two categories that are connected: library screening and rational design.

    Article Title: Molecule-rich solutions for achieving novel non-opioid analgesics.
    Article Snippet: - Alternatives to opioids in pain medication are urgently needed - Ion channels, GPCRs, and transporters are potential new analgesic targets - Multitarget molecule-rich approaches may be the best alternative Despite their efficacy, opioids have long been associated with risks of addiction, tolerance, and dependence, leaving an unmet clinical need for pain treatment.

    Article Title: Novel Alaninamide Derivatives with Drug-like Potential for Development as Antiseizure and Antinociceptive Therapies—In Vitro and In Vivo Characterization
    Article Snippet: One of the promising therapeutic strategies in DRE involves development of multimodal (multitarget/multifunctional) molecules modulating different molecular targets and thereby overcoming the issues associated with polytherapy, which is often used in this condition.

    Hybridization:

    Article Title: Design, Synthesis, Antitumor, and Antiplasmodial Evaluation of New 7-Chloroquinoline–Benzimidazole Hybrids
    Article Snippet: .. The hybridization approach attempts to produce a multitarget molecule that would overcome the drawbacks of combination therapy such as drug resistance, dose limitations, and adverse drug–drug effects [ , ]. ..



    Similar Products

    small-molecule and a multitarget tki anlotinib  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals small-molecule and a multitarget tki anlotinib
    Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + <t>anlotinib;</t> Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.
    Small Molecule And A Multitarget Tki Anlotinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget+molecule/anlotinib/pmc12198539-51-6-4
    Average 90 stars, based on 1 article reviews
    small-molecule and a multitarget tki anlotinib - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    small molecule multitarget drugs lenvatinib  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals small molecule multitarget drugs lenvatinib
    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the <t>lenvatinib</t> group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.
    Small Molecule Multitarget Drugs Lenvatinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget+molecule/lenvatinib/pmc12097796-219-5-3
    Average 90 stars, based on 1 article reviews
    small molecule multitarget drugs lenvatinib - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    cheis based hit(lead)-multitarget small molecules  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals cheis based hit(lead)-multitarget small molecules
    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the <t>lenvatinib</t> group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.
    Cheis Based Hit(lead) Multitarget Small Molecules, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget+molecule/cheis+based+hit+lead++multitarget+small+molecules/pm40158868-2-44-47
    Average 90 stars, based on 1 article reviews
    cheis based hit(lead)-multitarget small molecules - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    multitarget molecule-rich approaches  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget molecule-rich approaches
    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the <t>lenvatinib</t> group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.
    Multitarget Molecule Rich Approaches, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget+molecule/multitarget+molecule/pm40081520-11-17-22
    Average 90 stars, based on 1 article reviews
    multitarget molecule-rich approaches - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    multitarget molecules  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget molecules
    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the <t>lenvatinib</t> group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.
    Multitarget Molecules, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget+molecule/multitarget+molecule/pm39950933-120-0-0
    Average 90 stars, based on 1 article reviews
    multitarget molecules - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    small molecule acting as multitarget inhibitor  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals small molecule acting as multitarget inhibitor
    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the <t>lenvatinib</t> group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.
    Small Molecule Acting As Multitarget Inhibitor, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget+molecule/small+molecule+acting+as+multitarget+inhibitor/pm39527665-356-6-6
    Average 90 stars, based on 1 article reviews
    small molecule acting as multitarget inhibitor - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    multitarget-directed molecules 2024, 29, 4683 ligands  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget-directed molecules 2024, 29, 4683 ligands
    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the <t>lenvatinib</t> group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.
    Multitarget Directed Molecules 2024, 29, 4683 Ligands, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget+molecule/multitarget+directed+molecules+2024++29++4683+ligands/pm39407611-665-5-8
    Average 90 stars, based on 1 article reviews
    multitarget-directed molecules 2024, 29, 4683 ligands - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    multitarget small molecules  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget small molecules
    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the <t>lenvatinib</t> group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.
    Multitarget Small Molecules, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget+molecule/small+molecules/pm39092855-242-6-6
    Average 90 stars, based on 1 article reviews
    multitarget small molecules - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    multitarget molecule  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget molecule
    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the <t>lenvatinib</t> group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.
    Multitarget Molecule, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multitarget+molecule/multitarget+molecule/pmc11243327-103-7-7
    Average 90 stars, based on 1 article reviews
    multitarget molecule - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + anlotinib; Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.

    Journal: Therapeutic Advances in Medical Oncology

    Article Title: Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis

    doi: 10.1177/17588359251348310

    Figure Lengend Snippet: Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + anlotinib; Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.

    Article Snippet: A small-molecule and a multitarget TKI, Anlotinib, has indicated an increased OS of 2.4 months when applied as a later-line therapy for ES-SCLC patients compared to placebo., Therefore, NMPA has recommended anlotinib as a third-line or subsequent-line treatment option for ES-SCLC patients.

    Techniques:

    HRs, ORs, and their 95% confidence intervals from network meta-analysis of different first-line therapeutic regimens in ES-SCLC patients. (a) HRs and 95% CI for overall survival (upper triangle in yellow) and progression-free survival (lower triangle in green). The hazard ratio < 1.00 provides better survival benefits. (b) ORs and 95% CI for objective response rate (upper triangle in yellow) and grade ⩾ 3 adverse events (lower triangle in green). OR < 1.00 indicates a better efficacy or more toxicity. The results are presented as column-defined treatment versus row-defined treatment. Significant results are in bold. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Chemo, Chemotherapy; CI, confidence intervals; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; HR, hazard ratios; Nivo, Nivolumab; OR, odds ratio; Pemb, Pembrolizumab; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.

    Journal: Therapeutic Advances in Medical Oncology

    Article Title: Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis

    doi: 10.1177/17588359251348310

    Figure Lengend Snippet: HRs, ORs, and their 95% confidence intervals from network meta-analysis of different first-line therapeutic regimens in ES-SCLC patients. (a) HRs and 95% CI for overall survival (upper triangle in yellow) and progression-free survival (lower triangle in green). The hazard ratio < 1.00 provides better survival benefits. (b) ORs and 95% CI for objective response rate (upper triangle in yellow) and grade ⩾ 3 adverse events (lower triangle in green). OR < 1.00 indicates a better efficacy or more toxicity. The results are presented as column-defined treatment versus row-defined treatment. Significant results are in bold. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Chemo, Chemotherapy; CI, confidence intervals; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; HR, hazard ratios; Nivo, Nivolumab; OR, odds ratio; Pemb, Pembrolizumab; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.

    Article Snippet: A small-molecule and a multitarget TKI, Anlotinib, has indicated an increased OS of 2.4 months when applied as a later-line therapy for ES-SCLC patients compared to placebo., Therefore, NMPA has recommended anlotinib as a third-line or subsequent-line treatment option for ES-SCLC patients.

    Techniques:

    Bayesian ranking profiles of comparable treatments on efficacy and safety for ES-SCLC patients. Ranking plots indicate the probability of each comparable immunotherapy combination being ranked from first to last on OS, PFS, ORR, and grade ⩾ 3 AEs. Adeb, Adebrelimab; AE, adverse event; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; Nivo, Nivolumab; ORR, overall response rate; OS, overall survival; Pemb, Pembrolizumab; PFS, progression-free survival; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.

    Journal: Therapeutic Advances in Medical Oncology

    Article Title: Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis

    doi: 10.1177/17588359251348310

    Figure Lengend Snippet: Bayesian ranking profiles of comparable treatments on efficacy and safety for ES-SCLC patients. Ranking plots indicate the probability of each comparable immunotherapy combination being ranked from first to last on OS, PFS, ORR, and grade ⩾ 3 AEs. Adeb, Adebrelimab; AE, adverse event; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; Nivo, Nivolumab; ORR, overall response rate; OS, overall survival; Pemb, Pembrolizumab; PFS, progression-free survival; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.

    Article Snippet: A small-molecule and a multitarget TKI, Anlotinib, has indicated an increased OS of 2.4 months when applied as a later-line therapy for ES-SCLC patients compared to placebo., Therefore, NMPA has recommended anlotinib as a third-line or subsequent-line treatment option for ES-SCLC patients.

    Techniques:

    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the lenvatinib group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.

    Journal: Liver Cancer

    Article Title: Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

    doi: 10.1159/000545545

    Figure Lengend Snippet: Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the lenvatinib group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.

    Article Snippet: Among small molecule multitarget drugs, lenvatinib has the highest ORR of 18.8% [ ].

    Techniques:

    Swimmer plot of overall survival and treatment duration in lenvatinib and bevacizumab groups.

    Journal: Liver Cancer

    Article Title: Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

    doi: 10.1159/000545545

    Figure Lengend Snippet: Swimmer plot of overall survival and treatment duration in lenvatinib and bevacizumab groups.

    Article Snippet: Among small molecule multitarget drugs, lenvatinib has the highest ORR of 18.8% [ ].

    Techniques:

    Tumor responses rates based on mRECIST in the lenvatinib group and the bevacizumab group before PSM and after PSM.

    Journal: Liver Cancer

    Article Title: Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

    doi: 10.1159/000545545

    Figure Lengend Snippet: Tumor responses rates based on mRECIST in the lenvatinib group and the bevacizumab group before PSM and after PSM.

    Article Snippet: Among small molecule multitarget drugs, lenvatinib has the highest ORR of 18.8% [ ].

    Techniques: